CFM
MXCT icon

Catalyst Funds Management’s MaxCyte MXCT Stock Holding History

Catalyst Funds Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,700
Closed -$73.6K – 544
2024
Q4 		$73.6K Buy
+17,700
New +$66.9K 0.02% 275

Other funds holding MXCT

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Catalyst Funds Management's MXCT Position: Q1 2025 in Review

Catalyst Funds Management sold out of MaxCyte (MXCT) in Q1 2025, closing a stake of 17,700 shares — an estimated $73.6K sold.

Catalyst Funds Management first reported a position in MXCT in Q4 2024 and held it in 1 quarter. The position peaked at $73.6K in Q4 2024. 115 funds tracked by Wall St. Rank hold MXCT as of Q1 2025.

  • Catalyst Funds Management reported no remaining MaxCyte position as of Q1 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 17,700 MaxCyte shares in Q1 2025, an estimated $73.6K.
  • Catalyst Funds Management first reported a position in MaxCyte in Q4 2024 and held it in 1 quarter.
  • Catalyst Funds Management's MaxCyte position peaked at $73.6K in Q4 2024.
  • 115 funds tracked by Wall St. Rank held MaxCyte as of Q1 2025.

Based on Catalyst Funds Management's 13F filing for Q1 2025, filed 14 May 2025.